Ibogaine by David Dardashti to Illuminate the Transformative Ibogaine Experience at Psychedelic Conference 2025
The core of the discussion will center on the therapeutic journey of Ibogaine. Patients describe the experience as a profound, introspective voyage through the past, present, and even potential future aspects of their lives. Unlike other therapies, Ibogaine often facilitates a unique perspective, allowing individuals to revisit significant life events and internalize them not from their own clouded emotional state, but from the detached, objective viewpoint of an outside observer. This remarkable shift in perspective enables deep understanding, reconciliation, and the ability to release long-held emotional burdens, fostering genuine personal growth and a renewed sense of purpose.
Ibogaine by David Dardashti emphasizes highly individualized treatment protocols. The duration of an Ibogaine treatment varies, ranging from a focused 4-day experience to a comprehensive 21-day program, depending on the individual's specific needs, medical history, and the nature of their condition. Dosing is meticulously spread throughout the treatment period, starting with an initial transformative dose designed to interrupt cycles of dependence or deeply seated psychological patterns. This is often followed by carefully administered booster doses and, for longer programs, microdoses that support integration, neurogenesis, and sustained well-being in the weeks following the primary experience. This structured approach ensures both safety and maximal therapeutic benefit.
"Ibogaine therapy, when administered with profound care and expertise, is not merely a detox; it is an awakening," says David Dardashti. "We guide individuals through a process that helps them confront their past, understand their present, and envision a healthier future. It's about empowering them to rewrite their narrative from a place of clarity and self-compassion, leading to truly sustainable transformation."
Attendees of the Psychedelic Conference 2025 are invited to engage with Ibogaine by David Dardashti on Day 2 to gain a comprehensive understanding of this powerful plant medicine, its meticulous application, and the life-altering benefits it offers to those ready to embark on a journey of profound self-discovery and healing.
About Ibogaine by David Dardashti:
Ibogaine by David Dardashti is dedicated to providing safe, compassionate, and highly effective Ibogaine treatments. With a focus on individualized care, medical oversight, and comprehensive aftercare, the centers guide individuals towards sustainable recovery and improved mental well-being using the transformative properties of Ibogaine.
About Psychedelic Conference 2025:
The Psychedelic Conference 2025 is a leading international event bringing together researchers, practitioners, policymakers, and advocates to explore the latest advancements, therapeutic applications, and societal implications of psychedelic medicines.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relations ir@ (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@ (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ (628) 234-3889
Globe and Mail
an hour ago
- Globe and Mail
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
Key Points Obesity is linked to many diseases, including cancer. A recent study found that tumors in mice shrank after they were administered tirzepatide. It could take years for GLP-1 drugs to obtain regulatory approval as cancer-related treatments. 10 stocks we like better than Eli Lilly › GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (NYSE: LLY) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help. But a growing number of studies suggest that they could be useful in indications beyond diabetes and weight loss. One particularly intriguing study involves cancer, and it reveals a potential role for GLP-1 agonists in that area of healthcare. If GLP-1 drugs end up obtaining approval as treatments related to oncology, that could unlock a massive new sales growth opportunity for them. That could make a stock like Eli Lilly an even better buy than it is today. Study finds tumors shrank in mice with the help of tirzepatide Previous studies have shown that when people shed weight, they reduce their risks of developing many illnesses, among them, cancer. But a recent study presented at the Endocrine Society's annual meeting found that GLP-1 agonists could have a more direct impact: They may also reduce the size of breast cancer tumors. The study was modest in scope and not on human patients: Its subjects were 16 mice. Those mice that received injections of tirzepatide (the active ingredient in both Zepbound and Mounjaro) for 16 weeks lost around 20% of their weight, which was comparable to the weight loss that humans achieve while on the drug. And their tumors shrank by around that percentage as well. "Researchers found that tumor volume was significantly correlated with body weight," reported ScienceDaily. But even though these results are promising, they are very preliminary. It would take years of studies on humans before a GLP-1 drug could conceivably obtain a label expansion for use in treating any type of cancer. However, there is hope that GLP-1 drugs can do more than just help with diabetes and weight reduction. Regulators did approve tirzepatide for the treatment of obstructive sleep apnea last year. And another study found that it can help reduce the risk of heart failure. As more research is done on GLP-1 drugs, the number of indications they can treat may grow significantly. And if tirzepatide is able to help treat cancer, it could make this already massive drug a sales behemoth for Eli Lilly. Business has been booming for Eli Lilly, and more growth is still ahead Eli Lilly has already been performing incredibly well, thanks in large part to its highly successful GLP-1 drugs. In the first three months of 2025, its sales soared by 45% year over year to $12.7 billion. Zepbound and Mounjaro combined to make up $6.2 billion of that tally. And what's exciting is that these drugs are still in their early growth stages. That's a big reason why Eli Lilly stock trades at a hefty premium of 65 times its trailing earnings. Its 5-year price-to-earnings growth (PEG) multiple of 1.2 indicates, however, that it may not be that expensive relative to its medium-term growth potential. Eli Lilly stock is a no-brainer buy Although the stock may not look cheap, Eli Lilly could be among the best long-term investments you can add to your portfolio today. If tirzepatide racks up more indications and Eli Lilly's already approved drugs reach greater numbers of people, its sales and profits are likely to rise in the years ahead. This year, the stock is up a modest 4% as the hype around it appears to have cooled. But if you're in it for the long haul, it would be hard to go wrong with Eli Lilly. It may just be one of the best growth stocks in the healthcare sector. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
2 hours ago
- Globe and Mail
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in the second quarter of 2024. 'Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. 'We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth, starting with data from the TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis expected in September that could fundamentally improve options for patients with this progressive, deadly disease with few treatments available. 'Equally, our strong financial position, confidence in these upcoming catalysts, and belief in our share price potential has led our Board of Directors to authorize up to $1 billion in share repurchases, affirming our commitment to a robust and balanced capital allocation philosophy.' Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, 'We're proud of the continued record performance for Tyvaso DPI, a best-in-class treprostinil dry powder inhaler that allows the flexibility of one breath per cartridge, four times a day, with low inspiratory effort. Further, no other commercially available treprostinil dry powder inhaler has been clinically studied with published data at higher doses 1,2 or prescribed by more physicians to more patients than Tyvaso DPI. 'We expect continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.' Second Quarter 2025 Financial Results Key financial highlights include (dollars in millions, except per share data): Revenues The table below presents the components of total revenues (dollars in millions): Three Months Ended June 30, Dollar Change Percentage Change 2025 2024 Net product sales: Tyvaso DPI ®(1) $ 315.2 $ 258.3 $ 56.9 22 % Nebulized Tyvaso ®(1) 154.4 139.9 14.5 10 % Total Tyvaso 469.6 398.2 71.4 18 % Remodulin ®(2) 134.7 147.3 (12.6 ) (9 )% Orenitram ® 123.9 107.1 16.8 16 % Unituxin ® 58.4 51.7 6.7 13 % Adcirca ® 6.5 5.7 0.8 14 % Other 5.5 4.9 0.6 12 % Total revenues $ 798.6 $ 714.9 $ 83.7 12 % (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity ® Pump. Total Tyvaso revenues grew by 18 percent to $469.6 million in the second quarter of 2025, compared to $398.2 million in the second quarter of 2024. The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $54.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in Tyvaso DPI quantities sold was primarily due to continued growth in the number of patients following the product's launch, including growth in utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act ( IRA). The growth in Nebulized Tyvaso revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The growth in Orenitram revenues resulted primarily from an increase in quantities sold of $10.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in quantities sold was driven, at least in part, by increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the IRA. The table below presents the breakdown of total revenues between the United States and rest-of-world ( ROW) (in millions): Three Months Ended June 30, 2025 2024 U.S. ROW Total U.S. ROW Total Net product sales: Tyvaso DPI (1) $ 314.8 $ 0.4 $ 315.2 $ 258.3 $ — $ 258.3 Nebulized Tyvaso (1) 140.5 13.9 154.4 130.2 9.7 139.9 Total Tyvaso 455.3 14.3 469.6 388.5 9.7 398.2 Remodulin (2) 113.7 21.0 134.7 122.5 24.8 147.3 Orenitram 123.9 — 123.9 107.1 — 107.1 Unituxin 55.4 3.0 58.4 46.8 4.9 51.7 Adcirca 6.5 — 6.5 5.7 — 5.7 Other 5.0 0.5 5.5 4.6 0.3 4.9 Total revenues $ 759.8 $ 38.8 $ 798.6 $ 675.2 $ 39.7 $ 714.9 (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity Pump. Expenses Cost of sales. The table below summarizes cost of sales by major category (dollars in millions): (1) See Share-based compensation below. Cost of sales, excluding share-based compensation. Cost of sales for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to an increase in: (1) royalty expense resulting from a growth in revenues; and (2) reserve expense resulting from increased production. Research and development. The table below summarizes the nature of research and development expense by major expense category (dollars in millions): 2025 2024 Category: External research and development (1) $ 62.4 $ 49.4 $ 13.0 26 % Internal research and development (2) 55.9 44.5 11.4 26 % Share-based compensation expense (3) 8.1 8.6 (0.5 ) (6 )% Other (4) 7.6 37.1 (29.5 ) (80 )% Total research and development expense $ 134.0 $ 139.6 $ (5.6 ) (4 )% (1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. (2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. (3) See Share-based compensation below. (4) Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations. Research and development, excluding share-based compensation. Research and development expense for the three months ended June 30, 2025 decreased as compared to the same period in 2024, primarily due to $36.0 million in upfront non-refundable license payments for drug delivery device technologies in 2024, partially offset by: (1) increased expenditures in 2025 related to manufactured organ and organ alternative projects; and (2) a $5.0 million milestone payment made in 2025 for drug delivery device technologies. Selling, general, and administrative. The table below summarizes selling, general, and administrative expense by major category (dollars in millions): 2025 2024 Category: General and administrative (1) $ 131.1 $ 113.0 $ 18.1 16 % Impairment of property, plant, and equipment ( PP&E) 21.7 — 21.7 NM (2) Sales and marketing 31.0 25.4 5.6 22 % Share-based compensation expense (3) 28.7 39.2 (10.5 ) (27 )% Total selling, general, and administrative expense $ 212.5 $ 177.6 $ 34.9 20 % (1) Excluding impairment of PP&E. See Impairment of PP&E section below. (2) Calculation is not meaningful. (3) See Share-based compensation below. General and administrative, excluding impairment of PP&E and share-based compensation. General and administrative expense for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to: (1) personnel expense due to growth in headcount; and (2) legal expenses related to litigation matters. Impairment of PP&E. During the three months ended June 30, 2025, we recorded a $21.7 million impairment charge to write down the carrying value of certain PP&E. Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions): 2025 2024 Category: Stock options $ 11.1 $ 8.1 $ 3.0 37 % Restricted stock units 26.0 19.2 6.8 35 % Share tracking awards plan ( STAP) — 21.9 (21.9 ) (100 )% Employee stock purchase plan 0.7 0.5 0.2 40 % Total share-based compensation expense $ 37.8 $ 49.7 $ (11.9 ) (24 )% The decrease in share-based compensation expense for the three months ended June 30, 2025, as compared to the same period in 2024, was primarily due to a decrease in STAP expense, as all remaining STAP awards were exercised during the first quarter of 2025. Income tax expense. Income tax expense for the three months ended June 30, 2025 and 2024 was $98.9 million and $77.2 million, respectively. Our effective income tax rate ( ETR) for the three months ended June 30, 2025 and 2024 was 24 percent and 22 percent, respectively. Our ETR for the three months ended June 30, 2025 increased compared to our ETR for the three months ended June 30, 2024, primarily due to a decrease in excess tax benefits from share-based compensation. Webcast We will host a webcast to discuss our second quarter 2025 financial results on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at An investor presentation is available now, and after the webcast a replay of the webcast will also be available, at the same location on our website. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation ( PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our share repurchase program, the anticipated timing and outcome of the TETON 2 and TETON 1 clinical trials of Nebulized Tyvaso in idiopathic pulmonary fibrosis, including potential for these studies to improve options for patients with this disease; the anticipated readout of the ADVANCE OUTCOMES clinical trial of ralinepag; our near- to medium-term catalysts positioned for sustained long-term growth; our expectation of continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 30, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason. ADCIRCA is a registered trademark of Eli Lilly and Company. Three Months Ended June 30, 2025 2024 (Unaudited) Total revenues $ 798.6 $ 714.9 Operating expenses: Cost of sales 87.6 77.8 Research and development 134.0 139.6 Selling, general, and administrative 212.5 177.6 Total operating expenses 434.1 395.0 Operating income 364.5 319.9 Interest income 51.3 46.2 Interest expense (7.3 ) (11.6 ) Other (expense) income, net (0.1 ) 0.8 Total other income, net 43.9 35.4 Income before income taxes 408.4 355.3 Income tax expense (98.9 ) (77.2 ) Net income $ 309.5 $ 278.1 Net income per common share: Basic $ 6.86 $ 6.26 Diluted $ 6.41 $ 5.85 Weighted average number of common shares outstanding: Basic 45.1 44.4 Category: Earnings
